161 related articles for article (PubMed ID: 29164901)
1. Co-Amorphous Formation of High-Dose Zwitterionic Compounds with Amino Acids To Improve Solubility and Enable Parenteral Delivery.
Zhu S; Gao H; Babu S; Garad S
Mol Pharm; 2018 Jan; 15(1):97-107. PubMed ID: 29164901
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
3. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
4. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
[TBL] [Abstract][Full Text] [Related]
5. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
6. Non-salt based co-amorphous formulation produced by freeze-drying.
Suleiman Alsalhi M; Royall PG; Al-Obaidi H; Alsalhi A; Cilibrizzi A; Chan KLA
Int J Pharm; 2023 Oct; 645():123404. PubMed ID: 37714312
[TBL] [Abstract][Full Text] [Related]
7. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
Parikh T; Sandhu HK; Talele TT; Serajuddin AT
Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
[TBL] [Abstract][Full Text] [Related]
10. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
11. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
12. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
13. Development of a screening method for co-amorphous formulations of drugs and amino acids.
Kasten G; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2016 Dec; 95():28-35. PubMed ID: 27531419
[TBL] [Abstract][Full Text] [Related]
14. Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability.
Hu D; Chen X; Li D; Zhang H; Duan Y; Huang Y
Int J Pharm; 2023 Mar; 635():122707. PubMed ID: 36764418
[TBL] [Abstract][Full Text] [Related]
15. Improvement in Inhalation Properties of Theophylline and Levofloxacin by Co-Amorphization and Enhancement in Its Stability by Addition of Amino Acid as a Third Component.
Ueda H; Hirakawa Y; Miyano T; Nakayama Y; Hatanaka Y; Uchiyama H; Tozuka Y; Kadota K
Mol Pharm; 2023 Dec; 20(12):6368-6379. PubMed ID: 37942959
[TBL] [Abstract][Full Text] [Related]
16. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
[TBL] [Abstract][Full Text] [Related]
17. Influence of variation in molar ratio on co-amorphous drug-amino acid systems.
Jensen KT; Larsen FH; Löbmann K; Rades T; Grohganz H
Eur J Pharm Biopharm; 2016 Oct; 107():32-9. PubMed ID: 27368747
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of amorphous ciprofloxacin-amino acid salts.
Mesallati H; Conroy D; Hudson S; Tajber L
Eur J Pharm Biopharm; 2017 Dec; 121():73-89. PubMed ID: 28919470
[TBL] [Abstract][Full Text] [Related]
19. Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement.
Li W; Song J; Li J; Li M; Tian B; He Z; Liu X; Fu Q
Int J Pharm; 2021 Sep; 607():120971. PubMed ID: 34363915
[TBL] [Abstract][Full Text] [Related]
20. Anomalous role change of tertiary amino and ester groups as hydrogen acceptors in eudragit E based solid dispersion depending on the concentration of naproxen.
Ueda H; Wakabayashi S; Kikuchi J; Ida Y; Kadota K; Tozuka Y
Mol Pharm; 2015 Apr; 12(4):1050-61. PubMed ID: 25654583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
